Clinical trials: Alzheimer Dementia (AD), open to volunteers
Tauopathies
Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A
The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 18F-JSS20-183A. The goal of this radiotracer is to quantify 4Repeat Tau (4Rtau) protein that is abnormally deposited in the brain…
- Trial name
- NCT06932809
- Testing
- 18F-JSS20-183A PET, Brain MRI, Amyloid PET
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- University of Pennsylvania
Alzheimer's Disease (AD), Cognitive Impairment
BioMIND Biospecimen Repository
The purpose of the BBR is to facilitate scientific research by serving as a local and external resource for the distribution of human blood and CSF biospecimens, together with their corresponding clinical data, to internal and…
- Trial name
- BBR (NCT07912736)
- Testing
- blood sample and optional csf collection
- Where
- Canada
- Volunteers
- 1,000 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD)
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
- Trial name
- NCT05395624
- Testing
- 18F-OP-801
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Ashvattha Therapeutics, Inc.
Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS)
[18F]ACI-19626 PET in TDP-43 Proteinopathies
The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein TDP-43 [involved in rare forms of dementia such as frontotemporal dementia (FTD) and in amyotrophic…
- Conditions
- Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS), TDP-43 Proteinopathies, Suspected Limbic Predominant Age-related TDP-43 Encephalopathy (LATE)
- Trial name
- NCT06891716
- Testing
- [18F]ACI-19626
- Where
- Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
Social Isolation, SCD
The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD)
The goal of this clinical trial is to learn about the effects of social isolation and social interaction on the risk of dementia progression and brain function in SCD 1.
- Conditions
- Social Isolation, SCD, Subjective Cognitive Decline, MCI
- Trial name
- NCT06335836
- Testing
- social isolation
- Where
- China
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
AD - Alzheimer's Disease, Sarcopenia
A Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients With Alzheimer's Disease.
The goal of this clinical trial is to learn if silkworm pupa powder works to improve the nutritional status of Alzheimer's disease patients.
- Conditions
- AD - Alzheimer's Disease, Sarcopenia, Asthenia
- Trial name
- AD (NCT07059871)
- Testing
- Silkworm pupa powder
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Zhejiang Hospital
Alzheimers Disease, Dementia
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU-002 (NCT06647498)
- Testing
- Remternetug
- Where
- 37 sites in United States, Argentina and 13 more
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Mild Cognitive Impairment (MCI), Dementia
An Insole and Ankle Device for Monitoring Cognitive Decline in Individuals at Risk for Alzheimer's Disease and/or Alzheimer's Disease Related Dementias (AD/ADRD)
This study tests an innovative system and service for collecting objective, consistent, and in-community gait parameters suitable for use as AD/ADRD biomarkers.
- Trial name
- NCT07127133
- Testing
- Insole and ankle device
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- HealthPartners Institute
Alzheimer Disease (AD), Unwanted Loneliness
Intervention to Reduce Unwanted Loneliness in Family Caregivers of People With Alzheimer
The absence of social relationships negatively affects physical, psychological, and social health. In other words, it alters people's quality of life and makes active aging difficult.
- Conditions
- Alzheimer Disease (AD), Unwanted Loneliness, Family Caregivers, Living With Process
- Trial name
- NCT07639645
- Testing
- Multimodal intervention to Reduce Unwanted Loneliness in Family Caregivers of People With Alzheimer
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- University of Valencia
Mild Cognitive Impairment, Alzheimer's Disease
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
- Trial name
- Bio-Hermes-002 (NCT06584357)
- Testing
- Biomarker Data Collection, MK6240
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GAP Innovations, PBC
Healthy, Subjective Cognitive Decline (SCD)
Sleep Stimulation to Enhance Waste Clearance in the Brain
This study aims to examine whether multi-night closed-loop auditory stimulation (CLAS) during sleep can enhance waste clearance and memory consolidation in healthy adults and older adults with subjective cognitive decline or mild…
- Conditions
- Healthy, Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI), Alzheimer Disease (AD)
- Trial name
- NCT07051239
- Testing
- Closed-loop acoustic stimulation
- Where
- Belgium
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Erasme University Hospital
Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia
Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function
This study is to evaluate the efficacy and safety of [18F]-APN-1607 Injection in PET imaging for detecting AD-related cognitive impairment.
- Trial name
- NCT07422857
- Testing
- [18F]-APN-1607
- Where
- 2 sites in China
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- JYAMS PET Research & Development Limited
Cognitive Dysfunction, Alzheimer Disease
ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults
This randomized, double-blind, placebo-controlled pilot trial will evaluate the effects of alpha-linolenic acid (ALA) supplementation on cognitive function, blood-brain barrier integrity, and brain vascular health in older adults…
- Conditions
- Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of
- Trial name
- NCT07392723
- Testing
- Alpha-Linolenic Acid (2.6 g/day)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Michal Schnaider Beeri, Ph.D.
Alzheimer s Disease, Major Depressive Disorder (MDD)
VR Pupillometry in Cognitive Impairment
With disease-modifying therapies emerging for dementia and related conditions, identifying cognitive decline as early as possible is increasingly important.
- Conditions
- Alzheimer s Disease, Major Depressive Disorder (MDD), Mild Cognitive Impairment, Dementia
- Trial name
- NCT07402356
- Where
- Germany
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Max-Planck-Institute of Psychiatry
Alzheimer's Disease, MCI-AD, Early Stage Alzheimer's Disease
Efficacy and Safety of Conventional Symptomatic Drugs Combined with Lencanizumab in the Treatment of Early Alzheimer's Disease: a Multicenter, Prospective, Observational Study
According to the World Health Organization, China will become the "oldest" country in the world by 2050, with 35 percent of the elderly population.
- Trial name
- NCT06868030
- Volunteers
- 120 people
- Sponsor
- First Hospital of China Medical University
Dry Age Related Macular Degeneration, Mild Cognitive Impairment (MCI)
Study to Detect Dendritic Cell Recruitment in Human Retina
The goal of this study is to develop an optimal method to detect the immune cells (cells that protect the human body against diseases) in association with abnormal conditions of the retina (light sensitive tissue in the back of…
- Conditions
- Dry Age Related Macular Degeneration, Mild Cognitive Impairment (MCI), Alzheimer Disease
- Trial name
- ICG-002 (NCT06872658)
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- MindImmune Therapeutics, Inc.
Parkinson's Disease (PD), Alzheimer's Disease (AD)
Quantification of Hsp90 in the Human Brain
This study tests the radiolabeled molecule ("tracer"), [¹¹C]HSP990, using positron emission tomography (PET) imaging to assess whether it can be used to measure levels of Heat Shock Protein 90 (Hsp90).
- Conditions
- Parkinson's Disease (PD), Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS)
- Trial name
- NCT07380204
- Testing
- [11C]HSP990 PET dosimetry, [11C]HSP990 PET test-retest, [11C]HSP990 simplified scan protocol
- Where
- Belgium
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Alzheimer Disease
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.
- Trial name
- NCT06585787
- Testing
- KarXT
- Where
- 296 sites in United States, Argentina and 23 more
- Volunteers
- 406 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Mild Cognitive Impairment, Alzheimer Disease
Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease
The goal of this clinical trial is to learn about how genetics and the response to stress predicts cognitive decline in individuals with mild cognitive impairment.
- Trial name
- Stress-AD (NCT05795634)
- Testing
- Trier Social Stress Test
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Johns Hopkins University
Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
REAl World Dementia OUTcomes: Observational Study
READ-OUT observational study will investigate blood-based biomarkers for dementia in real-world clinical settings. This 3-year observational study will include 3165 people, males or females aged 45 years or older, with cognitive…
- Conditions
- Alzheimer Disease (AD), Mild Cognitive Impairment (MCI), Dementia
- Trial name
- READ-OUT (NCT07238049)
- Where
- 27 sites in United Kingdom
- Volunteers
- 3,165 people
- Sponsor
- University of Oxford